Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2015 Nov 5;126(19):2186-92.
doi: 10.1182/blood-2015-05-644914. Epub 2015 Aug 19.

Multicenter Study of Combination DEP Regimen as a Salvage Therapy for Adult Refractory Hemophagocytic Lymphohistiocytosis

Affiliations
Free PMC article
Clinical Trial

Multicenter Study of Combination DEP Regimen as a Salvage Therapy for Adult Refractory Hemophagocytic Lymphohistiocytosis

Yini Wang et al. Blood. .
Free PMC article

Abstract

Hemophagocytic lymphohistiocytosis (HLH) is a refractory immune disorder with a significant risk of death. Although standard therapy has dramatically improved survival in HLH patients, approximately 30%, especially adults, show no response to current treatment strategies. This prospective study aimed to investigate the efficacy of liposomal doxorubicin treatment combined with etoposide and methylprednisolone (doxorubicin-etoposide-methylprednisolone; DEP) as a salvage therapy for adult refractory HLH. Adult patients who did not achieve at least partial response 2 weeks after initial standard HLH therapy were enrolled in this study between June 2013 and June 2014. Response to salvage therapy was assessed at 2 and 4 weeks after initiation of DEP therapy and patients were followed until death or until November 2014. Sixty-three refractory HLH patients were enrolled, including 29 cases of lymphoma-associated HLH, 22 cases of Epstein-Barr virus-associated HLH, and 4 cases of familial HLH. There were 8 cases with unknown underlying diseases. Seventeen cases (27.0%) achieved complete response and 31 cases (49.2%) achieved partial response. The overall response was 76.2% (48/63). Patients who showed no response to DEP died within 4 weeks after salvage therapy. Twenty-nine of the 48 patients who achieved partial or complete response survived to subsequent chemotherapy, allogenic hematopoietic stem cell transplantation, or splenectomy. Our study suggests that DEP regimen is an effective salvage regimen for adult refractory HLH, which can prolong patient survival as we continue to understand the responsible mechanisms and bridge the gap between HLH and its underlying diseases. This study was registered in the Chinese Clinical Trials Registry Platform (http://www.chictr.org.cn/) as ChiCTR-IPC-14005514.

Figures

Figure 1
Figure 1
Dosage of DEP regimen. The horizontal axis of this figure is a timeline, split into days.
Figure 2
Figure 2
Response rates of refractory HLH to DEP salvage treatment. CR, complete response; NR, no response; PR, partial response; unknown, unclear underlying disease.
Figure 3
Figure 3
Kaplan-Meier analysis of survival of patients receiving DEP salvage therapy. (A) Overall survival. (B) Comparison of the survival of patients with CR and PR. (C) Comparison of the survival of patients with different primary diseases.

Comment in

Similar articles

See all similar articles

Cited by 25 articles

See all "Cited by" articles

Publication types

Supplementary concepts

Feedback